ARCH Venture Management, LLC - Stock Holdings in 13F Filings (SEC)

Updated on March 15, 2026.

Based on 13F Filings filed with the SEC on February 17, 2026, for the 2025 Q4 period, ARCH Venture Management, LLC held in its portfolio 9 assets valued at $651,681,142 (i.e. $651.68M).

The most valuable assets in the portfolio included: MAZE THERAPEUTICS INC. ($170.69M), BEAM THERAPEUTICS INC. ($125.85M), and RAPPORT THERAPEUTICS INC. ($113.13M).

The chart below shows the top 9 valuable assets, and the table below shows the top 9 valuable assets.

You can see similar for other investment managers.

Related Topics: SEC Topic List.

Data Source: SEC.

Top Valuable Stocks in ARCH Venture Management, LLC Portfolio

MAZE THERAPEUTICS INC.

BEAM THERAPEUTICS INC.

RAPPORT THERAPEUTICS INC.

LYELL IMMUNOPHARMA INC.

VIR BIOTECHNOLOGY INC.

ERASCA INC.

GOSSAMER BIO INC.

10X GENOMICS INC.

Q32 BIO INC.

ARCH Venture Management, LLC - Stock Holdings in 13F Filings (SEC)

Items per page:

0 of 0

Name of Issuer	No. of Shares	Value ($)	Class
MAZE THERAPEUTICS INC.	4120053	170693796	COM
BEAM THERAPEUTICS INC.	4540132	125852459	COM
RAPPORT THERAPEUTICS INC.	3728738	113129911	COM
LYELL IMMUNOPHARMA INC.	2759072	84924236	COM NEW
VIR BIOTECHNOLOGY INC.	12916663	77887478	COM
ERASCA INC.	11055554	41126661	COM
GOSSAMER BIO INC.	8055916	24973340	COM
10X GENOMICS INC.	737539	12029261	CL A COM
Q32 BIO INC.	320482	1064000	COM